NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Johnson & Johnson Medical, China
Conditions: Atrial Fibrillation
To generate real world evidence to compare clinical outcomes and patient health-related quality of life, resulting from catheter ablation therapy with clinical outcome and patient health-related quality of life resulting from drug therapy in China. An economic model will be constructed, and using the clinical events evidence collected in this study, and China long-term disease progression and local disease cost data to perform a cost-effectiveness evaluation of Catheter Ablation versus Drug Therapy in AF (Paroxysmal plus Persistent AF) patients.
Sex: ALL
Age: 18 Years to 80 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Patients with paroxysmal or persistent AF eligible for catheter ablation * Age 18 to 80 years * Able and willing to comply with all pre,post and follow-up testing and requirements. * Be able to sign IRB/EC approved informed consent form. Exclusion Criteria: * Terminal illness with a life expectancy less than 1 year. * New York Heart Association (NYHA) Class III or IV * Previous recipient of catheter ablation therapy for AF * Bradycardia and previous recipient of pacemaker therapy * Previous recipient RFCA or ICD therapy * Uncontrolled hypertension * Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months * Patients with serious hepatic and renal diseases * Pregnant or prepare to be pregnant in one year * For drug therapy arm, if the subject cannot be contacted via phone or the subject shows his/her disagreement to this study at 30 day window, the subject will be withdrawn from this study.